Arunjyoti Bio Ventures Ltd files unaudited Q2 FY2026 results
The company submitted its unaudited financial results for the quarter ended 30 June 2026, together with a limited review report, on 9 July 2026.
What Arunjyoti Bio Ventures Ltd announced
On 9 July 2026, Arunjyoti Bio Ventures Ltd (BSE: 530881) submitted a filing to the Bombay Stock Exchange containing its unaudited financial results for the quarter ended 30 June 2026. The submission also includes a Limited Review Report prepared by the company’s auditors, confirming that the numbers are presented on a limited‑review basis and are not yet subject to a full audit.
Details of the unaudited results and limited review
The filing, titled “Un‑Audited Financial Results along with Limited Review Report for the Quarter Ended 30.06.2026”, provides the standard set of financial statements – balance sheet, profit & loss account, cash‑flow statement and accompanying notes – for the second quarter of the fiscal year 2025‑26. Because the results are unaudited, the auditors have performed only limited procedures to verify the consistency of the information with the underlying records. The limited review does not constitute an audit opinion, and the figures may be adjusted after the final audit is completed.
Key facts at a glance
| Detail | Value |
|---|---|
| Company | Arunjyoti Bio Ventures Ltd |
| BSE Code | 530881 |
| Filing date | 9 July 2026 (12:54 UTC) |
| Period covered | Quarter ended 30 June 2026 (Q2 FY2026) |
| Nature of filing | Un‑audited financial results + Limited Review Report |
| Source | BSE corporate filing (PDF) |
Why this matters for investors
The filing gives shareholders a first look at the company’s performance for the most recent quarter, albeit on an unaudited basis. Investors can use the numbers to gauge short‑term trends in revenue, profitability and cash generation, but should be aware that the figures may change after the full audit. The inclusion of a Limited Review Report signals that the auditors have performed basic verification, reducing the risk of material misstatement, yet it does not provide the assurance level of a statutory audit. Consequently, any investment decisions should consider the provisional nature of the data.
Conclusion
Arunjyoti Bio Ventures Ltd has complied with its regulatory obligation by filing unaudited Q2 FY2026 results together with a Limited Review Report on 9 July 2026. The numbers remain subject to final audit, and investors should await the audited statements for definitive financial information.
Frequently asked questions
Related stocks
Source filing: view original